Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CBX7 | O95931 | 1/20 | 0.33 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.33 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.33 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966722 | 0.90 | SMN1; SMN2 (0.34) | L3MBTL3L3MBTL1SMN1; SMN2KDM4EOPRL1 | |
| SCHEMBL14044233 | 0.85 | TSHR (0.35) | KDM4EOPRL1ALDH1A1 | |
| SCHEMBL21004524 | 0.84 | SMN1; SMN2 (0.33) | L3MBTL3L3MBTL1SMN1; SMN2ACHE | |
| SCHEMBL22921130 | 0.83 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL22958088 | 0.81 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11916104 | 0.81 | SMN1; SMN2 (0.40) | L3MBTL3L3MBTL1SMN1; SMN2KDM4EOPRL1 | |
| SCHEMBL17393082 | 0.80 | ALDH1A1 (0.38) | L3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9921756 | 0.80 | ALDH1A1 (0.38) | L3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL21214478 | 0.80 | KDM4E (0.45) | KDM4EOPRL1ALDH1A1HRH3 | |
| SCHEMBL21214477 | 0.80 | L3MBTL1 (0.36) | L3MBTL3L3MBTL1KDM4EOPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | L3MBTL3 2727/4885L3MBTL1 3945/4885SMN1; SMN2 4411/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | L3MBTL3 2727/4885L3MBTL1 3945/4885SMN1; SMN2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.